drugset / Trial / NCT01108458
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma
Timeline
- Start
- 2010-07
- Primary completion
- 2010-11
- Completion
- 2011-03
Outcome
Outcome not reported
Stopped: “Extreme toxicity of Pertuzumab and Erlotinib combination”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |